Cluster 0: obstruction bowel signs symptoms starting drugs history month current studyXx_NEWLINE_xXCluster 1: received prior patients treatment days therapy study chemotherapy dose previouslyXx_NEWLINE_xXCluster 2: study pregnant contraception agree participation adequate duration men women useXx_NEWLINE_xXCluster 3: patients prior study eligible disease patient history treatment days registrationXx_NEWLINE_xXCluster 4: consent informed signed sign dated form written patient institutional guidelinesXx_NEWLINE_xXCluster 5: platelets microliters plt dependent study day transfusion dose weeks treatmentXx_NEWLINE_xXCluster 6: composition compounds similar attributed chemical allergic reactions biologic used agentsXx_NEWLINE_xXCluster 7: karnofsky eastern cooperative ecog performance group oncology status kps greaterXx_NEWLINE_xXCluster 8: neutrophil absolute count mm microliters cells randomization enrollment weeks daysXx_NEWLINE_xXCluster 9: transfusion hemoglobin dl days blood past enrollment prior administration precedingXx_NEWLINE_xXCluster 10: platelet count mm days registration randomization prior mcl obtained mlXx_NEWLINE_xXCluster 11: limits normal institutional creatinine upper bilirubin days uln registration serumXx_NEWLINE_xXCluster 12: iuln bilirubin total upper registration institutional limit normal days priorXx_NEWLINE_xXCluster 13: mother breastfeeding discontinued treated pregnant excluded women study vx mlnXx_NEWLINE_xXCluster 14: transaminase aminotransferase uln serum ast glutamic alt liver sgot sgptXx_NEWLINE_xXCluster 15: absolute neutrophil mcl count growth hematopoietic factors days prior ulXx_NEWLINE_xXCluster 16: illness uncontrolled compliance social situations psychiatric intercurrent pectoris requirements arrhythmiaXx_NEWLINE_xXCluster 17: expectancy life greater months weeks appropriate patient estimated sequencing equalXx_NEWLINE_xXCluster 18: solid marrow tumors bone involvement known peripheral count anc patientsXx_NEWLINE_xXCluster 19: informed federal nature accordance guidelines sign written consent investigational institutionalXx_NEWLINE_xXCluster 20: hcv hepatitis hbv virus infection cleared known chronic patients eligibleXx_NEWLINE_xXCluster 21: requiring hypothyroidism autoimmune mellitus recur trigger psoriasis diabetes expected vitiligoXx_NEWLINE_xXCluster 22: state curative survival quality therapy prolong current proven life acceptableXx_NEWLINE_xXCluster 23: hemoglobin dl transfused level weeks unsupported hg mg randomization criterionXx_NEWLINE_xXCluster 24: cancer adequately treated surveillance cell program patient localized followed cervicalXx_NEWLINE_xXCluster 25: aminotransferase alt ast alanine aspartate uln iuln institutional days registrationXx_NEWLINE_xXCluster 26: corticosteroids steroids systemic prednisone mg inhaled immunosuppressive topical daily dosesXx_NEWLINE_xXCluster 27: transaminase aminotransferase serum sgpt glutamic sgot glutamate pyruvate oxaloacetic altXx_NEWLINE_xXCluster 28: complications resolved related infectious medical significant induction consolidation therapy cycleXx_NEWLINE_xXCluster 29: brain metastases treated patients stable prior treatment mri imaging untreatedXx_NEWLINE_xXCluster 30: investigational receiving agents patients ineligible participants study treatment trials cancerXx_NEWLINE_xXCluster 31: score lansky years karnofsky performance age patients status paralysis ambulatoryXx_NEWLINE_xXCluster 32: contraceptive measures reproductive pregnancy effective bilateral potential use time celibacyXx_NEWLINE_xXCluster 33: creatinine clearance gault min formula cockcroft ml calculated hour serumXx_NEWLINE_xXCluster 34: acquisition muga ejection fraction echocardiogram left gated ventricular multi scanXx_NEWLINE_xXCluster 35: sequencing antiretroviral combination immunodeficiency ineligible hiv biopsy virus human positiveXx_NEWLINE_xXCluster 36: understand document willingness ability written sign informed consent able guardianXx_NEWLINE_xXCluster 37: zubrod performance status patients registration days prior criteria step studyXx_NEWLINE_xXCluster 38: creatinine clearance min ml calculated serum measured uln crcl obtainedXx_NEWLINE_xXCluster 39: leukocytes mcl mm ul lower registration equal days initiation obtainedXx_NEWLINE_xXCluster 40: bilirubin upper normal limit total uln institutional times days priorXx_NEWLINE_xXCluster 41: swallow able pills absorb medication patients inability drug explained experiencingXx_NEWLINE_xXCluster 42: karnofsky performance status days step registration prior score sequencing ecogXx_NEWLINE_xXCluster 43: guardians legal parents sign written informed consent patients assent accordingXx_NEWLINE_xXCluster 44: mg years age dl males creatinine females serum maximum minXx_NEWLINE_xXCluster 45: higher neuropathy grade peripheral terminology common ctcae events adverse stepXx_NEWLINE_xXCluster 46: capsules swallow able patients tube nasogastric broken crushed inability tabletsXx_NEWLINE_xXCluster 47: major procedure surgical anticipation traumatic injury course days biopsy needXx_NEWLINE_xXCluster 48: vessels invading encasing major blood tumor subject contact indicate participantXx_NEWLINE_xXCluster 49: fda food nci institute met national studies requirements human administrationXx_NEWLINE_xXCluster 50: immunodeficiency hiv virus human known positive infection patients excluded individualsXx_NEWLINE_xXCluster 51: childbearing pregnancy test potential negative women serum registration days priorXx_NEWLINE_xXCluster 52: creatinine institutional normal levels clearance min ml upper limit patientsXx_NEWLINE_xXCluster 53: bp mmhg pressure blood antihypertensive diastolic systolic hypertension medications controlledXx_NEWLINE_xXCluster 54: platelets mm prior weeks days equivalent cell randomization ctcae enrollmentXx_NEWLINE_xXCluster 55: representatives assent parents legally authorized according appropriate guidelines sign writtenXx_NEWLINE_xXCluster 56: platelets mcl platelet transfusion transfusions requiring plt weeks equal cellsXx_NEWLINE_xXCluster 57: institutions identity process ensure board approval order open date enteredXx_NEWLINE_xXCluster 58: weeks entering recovered adverse events earlier administered nitrosoureas mitomycin agentsXx_NEWLINE_xXCluster 59: interstitial lung pneumonitis disease history pulmonary patients detection known symptomaticXx_NEWLINE_xXCluster 60: aminotransferase aspartate ast alanine upper alt normal limit uln institutionalXx_NEWLINE_xXCluster 61: consecutive female childbearing months mature naturally potential postmenopausal menses bilateralXx_NEWLINE_xXCluster 62: conjugated sum unconjugated age bilirubin uln upper limit normal subprotocolsXx_NEWLINE_xXCluster 63: monitoring comply safety opinion investigator able requirements eligible study patientsXx_NEWLINE_xXCluster 64: corticosteroids decreasing stable corticosteroid dose receiving days prior mri patientsXx_NEWLINE_xXCluster 65: platelet independent transfusion transfusions mm count enrollment defined receiving involvementXx_NEWLINE_xXCluster 66: oximetry pulse dyspnea rest air room exercise evidence intolerance breathingXx_NEWLINE_xXCluster 67: limits bilirubin normal total institutional uln upper gilberts direct registrationXx_NEWLINE_xXCluster 68: transplantation organ solid received allogeneic prior eligible patients marrow boneXx_NEWLINE_xXCluster 69: nodal lesions mm measured measurable axis short longest recorded accuratelyXx_NEWLINE_xXCluster 70: sgpt alt uln purpose alanine transaminase glutamate pyruvate aminotransferase serumXx_NEWLINE_xXCluster 71: step registration prior weeks mcl induction screening treatment optional preXx_NEWLINE_xXCluster 72: gog performance gynecologic status group oncology patients grade patient protocolXx_NEWLINE_xXCluster 73: bearing pregnancy test child negative females potential urine serum priorXx_NEWLINE_xXCluster 74: female pregnancy childbearing potential pregnant test negative patients result urineXx_NEWLINE_xXCluster 75: study agree contraception use male pregnant potential dose effective methodXx_NEWLINE_xXCluster 76: phase study weeks administered levels referred eligibility early recovered priorXx_NEWLINE_xXCluster 77: fraction echocardiogram shortening ejection radionuclide angiogram gated cardiac echo studyXx_NEWLINE_xXCluster 78: hepatitis antibody positive antigen hcv surface virus negative hbsag coreXx_NEWLINE_xXCluster 79: time measurements obtain prothrombin ptt thromboplastin pt normalized inr neurologicXx_NEWLINE_xXCluster 80: chemotherapy randomization surgery adjuvant administered days breast neoadjuvant cancer intervalXx_NEWLINE_xXCluster 81: marrow bone peripheral blood blasts biopsy aspirate patients performed involvementXx_NEWLINE_xXCluster 82: metastatic disease locally advanced patients evidence unresectable prior cancer definitiveXx_NEWLINE_xXCluster 83: uncontrolled infection eligible patients active patient step subprotocols excluded generalXx_NEWLINE_xXCluster 84: nursing childbearing pregnancy test pregnant negative women potential required registrationXx_NEWLINE_xXCluster 85: granulocytes ul anc cells mcl absolute extending explained experiencing experimentalXx_NEWLINE_xXCluster 86: eiaed epileptic drugs inducing anti enzyme taking patients previously enrolledXx_NEWLINE_xXCluster 87: forms medically willing sexually acceptable able contraception childbearing women menXx_NEWLINE_xXCluster 88: investigational currently drug receiving eligible patients anticancer therapy ineligible antiXx_NEWLINE_xXCluster 89: medications systemic adrenocortical anti tnf mineralocorticoids azathioprine orthostatic fludrocortisone doseXx_NEWLINE_xXCluster 90: months teaspoon dose hemoptysis red treatment study indicative bleeding hemorrhageXx_NEWLINE_xXCluster 91: ul platelet count transfusion cells independent cd unsupported platelets daysXx_NEWLINE_xXCluster 92: ischemic revascularization artery event procedures including fibrillation ventricular cerebrovascular attackXx_NEWLINE_xXCluster 93: thromboplastin partial time aptt ptt activated uln normal upper limitXx_NEWLINE_xXCluster 94: hodgkin expansion lymphoma cohort participants enrollment weeks prior dl serumXx_NEWLINE_xXCluster 95: pd anti prior therapy treatment agents patients ctla antibody progressionXx_NEWLINE_xXCluster 96: consent mandatory provide specific study entry informed tissue submission includingXx_NEWLINE_xXCluster 97: monoclonal hypersensitivity antibody reaction severe history ineligible grade exclusion stratumXx_NEWLINE_xXCluster 98: physical examination history registration days complete prior prestudy obtained patientsXx_NEWLINE_xXCluster 99: myelodysplastic mds aml leukemia myeloid syndrome acute suggestive features smearXx_NEWLINE_xXCluster 100: albumin dl serum days registration patients prior hypersensitivity mg inclusionXx_NEWLINE_xXCluster 101: syndrome fanconi anemia bloom telangiectasia shwachman kostmann ataxia known geneticXx_NEWLINE_xXCluster 102: protein urine urinalysis hour mg dipstick proteinuria screened obtained electrophoresisXx_NEWLINE_xXCluster 103: qtc prolong drugs alternatives interval receiving pointes torsades cause alternativeXx_NEWLINE_xXCluster 104: bisphosphonate hypercalcemia osteoporosis reasons taking therapy use metastasis symptomatic allowedXx_NEWLINE_xXCluster 105: triglyceride mg dl level fasting serum applicable mmol gsk nfXx_NEWLINE_xXCluster 106: peripheral anc neutrophil absolute mm count zubrod exposed experimental expertXx_NEWLINE_xXCluster 107: dmso immediate chemically dimethyl sulfoxide excipients idiosyncrasy delayed trametinib hypersensitivityXx_NEWLINE_xXCluster 108: left fraction ejection ventricular lvef normal institutional function indicated heartXx_NEWLINE_xXCluster 109: aallb aall apecb open enrolled enrollment patients classification project sampleXx_NEWLINE_xXCluster 110: expectancy life weeks patients estimated participants physician years procurement yearXx_NEWLINE_xXCluster 111: creatinine uln serum institutional times obtained grade prior days randomizationXx_NEWLINE_xXCluster 112: performance ecog status ps patients step registration score criteria greaterXx_NEWLINE_xXCluster 113: accepted males abstain sexually intercourse effective advised sexual contraception stronglyXx_NEWLINE_xXCluster 114: phosphatase alkaline uln involvement iuln days liver prior registration boneXx_NEWLINE_xXCluster 115: cancer breast invasive situ skin years malignancy carcinoma non melanomaXx_NEWLINE_xXCluster 116: inhibitor parp mek prior treatment kinase braf patients received therapyXx_NEWLINE_xXCluster 117: help occasional care karnofsky able performance status patient patients kpsXx_NEWLINE_xXCluster 118: abdominal abscess intra perforation gastrointestinal fistula months obstruction history diverticulitisXx_NEWLINE_xXCluster 119: permitting authorization release personal information health signed approved informed consentXx_NEWLINE_xXCluster 120: qt qtc interval milliseconds corrected torsades pointes prolongation long congenitalXx_NEWLINE_xXCluster 121: pre criteria registration eligibility inclusion step experiences experiencing experimental expertXx_NEWLINE_xXCluster 122: humanized anaphylactic proteins chimeric antibodies fusion allergic reactions severe hypersensitivityXx_NEWLINE_xXCluster 123: cardiac heart york association iii resulting activity iv new physicalXx_NEWLINE_xXCluster 124: corticosteroids brain anticonvulsants inducing enzyme subjects weeks stable metastases monthXx_NEWLINE_xXCluster 125: inr normalized international ratio time thromboplastin prothrombin ptt partial ulnXx_NEWLINE_xXCluster 126: transfusions hematologic evaluable toxicity provided red known platelet meet refractoryXx_NEWLINE_xXCluster 127: half lives whichever dose shorter days investigational minimum preceding studyXx_NEWLINE_xXCluster 128: major surgery days registration prior delayed immunotherapy toxicity treatment extensiveXx_NEWLINE_xXCluster 129: heart myocardial infarction failure months congestive angina history york associationXx_NEWLINE_xXCluster 130: creatinine mg dl serum registration iuln days prior umol levelXx_NEWLINE_xXCluster 131: glucose fasting mg dl blood diabetes serum mellitus age randomXx_NEWLINE_xXCluster 132: chinese hamster ovary recombinant products hypersensitivity antibodies cell human knownXx_NEWLINE_xXCluster 133: transplant stem cell allogeneic autologous prior graft host patients transplantationXx_NEWLINE_xXCluster 134: compounds composition chemical similar attributed allergic reactions biologic history mlnXx_NEWLINE_xXCluster 135: fistula gastrointestinal perforation history abdominal months repaired postoperative starting surgicallyXx_NEWLINE_xXCluster 136: tacrolimus cyclosporine transplant prevent host post versus graft marrow trialXx_NEWLINE_xXCluster 137: anthracycline intravesical therapy prior excluded systemic patients muscle previous urothelialXx_NEWLINE_xXCluster 138: pregnant breastfeeding women excluded study discontinued treatment drug dose refrainXx_NEWLINE_xXCluster 139: provide informed consent written able willing ability inability patients unableXx_NEWLINE_xXCluster 140: calc creatinine calculated min clearance ml uln upper mg normalXx_NEWLINE_xXCluster 141: chemotherapy cancer different allowable prior systemic note study egf currentXx_NEWLINE_xXCluster 142: weeks prior therapy study completed radiation shorter recovered half toxicityXx_NEWLINE_xXCluster 143: platelets mcl registration days prior obtained equal administration start stepXx_NEWLINE_xXCluster 144: gp inhibitors glycoprotein inducers bcrp strong binding member cypa adenosineXx_NEWLINE_xXCluster 145: females method agreed males contraceptive reproductive effective participate unless menarchalXx_NEWLINE_xXCluster 146: absolute neutrophil count ul anc peripheral unsupported cells lymphocyte weeksXx_NEWLINE_xXCluster 147: oral swallow medications ability medication retain able absorption gastrointestinal unableXx_NEWLINE_xXCluster 148: rvo retinal occlusion vein history evidence current risk csr intraocularXx_NEWLINE_xXCluster 149: dependency tpn hydration nutrition parenteral iv total intravenous current participantsXx_NEWLINE_xXCluster 150: anc neutrophil absolute count mcl registration days prior obtained equalXx_NEWLINE_xXCluster 151: hemoglobin dl hgb achieve intervention transfusion acceptable note use daysXx_NEWLINE_xXCluster 152: overlap fields radiation result pelvis therapy neck head irradiation previousXx_NEWLINE_xXCluster 153: investigational agent receiving received treatment days neoplasm type patients doseXx_NEWLINE_xXCluster 154: nursing pregnant women mothers patients excluded unwilling pregnancy step birthXx_NEWLINE_xXCluster 155: anticonvulsants seizure inducing enzyme disorder controlled enrolled seizures patients nonXx_NEWLINE_xXCluster 156: area surface body bsa enrollment patients time study mg levelXx_NEWLINE_xXCluster 157: adverse events common terminology ctcae grade criteria version alopecia priorXx_NEWLINE_xXCluster 158: antiretroviral combination hiv ineligible immunodeficiency positive human virus therapy patientsXx_NEWLINE_xXCluster 159: recist measurable response criteria solid evaluation disease tumors evaluable definedXx_NEWLINE_xXCluster 160: alchemist screen alliance registered trial randomization prior patients express expressingXx_NEWLINE_xXCluster 161: histologically confirmed cytologically cancer diagnosis metastatic patients proven unresectable cellXx_NEWLINE_xXCluster 162: age years score walk wheelchair ambulatory assessing performance lansky patientsXx_NEWLINE_xXCluster 163: carcinoma cell squamous skin basal situ malignancies treated malignancy yearsXx_NEWLINE_xXCluster 164: specific informed consent provide study registration signed representative prior legallyXx_NEWLINE_xXCluster 165: protein urine ratio upc creatinine upcr proteinuria hour dipstick collectionXx_NEWLINE_xXCluster 166: mg dl years male female age creatinine gender radioisotope gfrXx_NEWLINE_xXCluster 167: stage iv iii disease patients cancer ii carcinoma ovarian diagnosisXx_NEWLINE_xXCluster 168: transfusions hemoglobin rbc dl red receive blood cell requiring involvementXx_NEWLINE_xXCluster 169: history coronary heart evidence cardiac controlled mmhg current defined subjectsXx_NEWLINE_xXCluster 170: sensory motor neuropathy grade ctcae peripheral terminology common equal eventsXx_NEWLINE_xXCluster 171: blocks slides tissue notified unavailable sent chair enrollment available studyXx_NEWLINE_xXCluster 172: myelosuppressive days dose enrollment prior chemotherapy agent immunomodulatory elapsed nitrosoureaXx_NEWLINE_xXCluster 173: step randomization ii prior days dl bilirubin mg cells mmXx_NEWLINE_xXCluster 174: hiv licensed assay record approved documentation test rapid western blotXx_NEWLINE_xXCluster 175: return enrolling institution follow willing alliance willingness monitoring active phaseXx_NEWLINE_xXCluster 176: radiation therapy prior chemotherapy received weeks patients pelvic elapsed treatmentXx_NEWLINE_xXCluster 177: eligibility criteria step randomization registration induction meet preregistration screening operativeXx_NEWLINE_xXCluster 178: radiotherapy weeks prior chemotherapy patients therapy entering study mitomycin nitrosoureasXx_NEWLINE_xXCluster 179: edition ajcc committee joint th american cancer stage staging nsclcXx_NEWLINE_xXCluster 180: white wbc blood ul count cell cells randomization prior obtainedXx_NEWLINE_xXCluster 181: days events adverse infusion growth known agent elapsed occurring extendedXx_NEWLINE_xXCluster 182: rankl denosumab atezolizumab discontinue treatment inhibitor requiring patients kappa requireXx_NEWLINE_xXCluster 183: hsp inhibitor prior therapy received treatment patients zubrod expiratory experiencesXx_NEWLINE_xXCluster 184: immunocompromised hiv positive immunodeficiency virus human known corticosteroids related patientsXx_NEWLINE_xXCluster 185: laboratory clia certified mutation braf improvement clinical amendments approved mutationsXx_NEWLINE_xXCluster 186: years age lansky performance ecog karnofsky scores cooperative eastern correspondingXx_NEWLINE_xXCluster 187: qt syndrome long congenital qtc family history ecg corrected msecXx_NEWLINE_xXCluster 188: standard survival prolong therapy progressed histologically tumors solid shown existXx_NEWLINE_xXCluster 189: anc neutrophil absolute mm count cells days registration prior obtainedXx_NEWLINE_xXCluster 190: pregnant partner participating inform suspect immediately woman physician treating studyXx_NEWLINE_xXCluster 191: cns nervous central metastases involvement patients disease brain lumbar punctureXx_NEWLINE_xXCluster 192: cytochrome subfamily cypa family polypeptide strong inhibitors inducers cypc medicationsXx_NEWLINE_xXCluster 193: brain metastases carcinomatous meningitis remained stable trial patients clinical metastaticXx_NEWLINE_xXCluster 194: reproductive contraceptive sexually effective method agreed duration potential use participationXx_NEWLINE_xXCluster 195: infection exhibiting bacterial fungal signs despite improvement antibiotics symptoms appropriateXx_NEWLINE_xXCluster 196: cancer adequately treated cell basal patient squamous free situ skinXx_NEWLINE_xXCluster 197: corticosteroid dose modify corticosteroids days elapsed immune decreasing stable relatedXx_NEWLINE_xXCluster 198: signs symptoms cycle infection day weeks prior tuberculosis clinical activeXx_NEWLINE_xXCluster 199: choice apecsc actionable match assignment given molecular analysis mutation presenceXx_NEWLINE_xXCluster 200: lln calcium serum magnesium potassium lower phosphorus limit normal delayingXx_NEWLINE_xXCluster 201: feeding breast women pregnant females eligible lactating study girls menarchalXx_NEWLINE_xXCluster 202: permit circumstances follow completion required study travel issue instance patientsXx_NEWLINE_xXCluster 203: fathering willing childbearing birth control child potential medically form treatedXx_NEWLINE_xXCluster 204: hiv retroviral positive opportunistic virus haart immunodeficiency human cd regimenXx_NEWLINE_xXCluster 205: therapy prior chemotherapy cancer systemic patients hormonal treatment anti radiationXx_NEWLINE_xXCluster 206: retain stomach malabsorption bowels alter medication abnormalities swallow absorption majorXx_NEWLINE_xXCluster 207: pressure blood mmhg hypertension systolic diastolic hypertensive uncontrolled controlled hgXx_NEWLINE_xXCluster 208: egfr exon tki tm mutation generation erlotinib deletion treatment testingXx_NEWLINE_xXCluster 209: lln echo lower left echocardiogram ejection ventricular fraction institutional limitXx_NEWLINE_xXCluster 210: male female years creatinine age gender follows serum based radioisotopeXx_NEWLINE_xXCluster 211: pt anticoagulant ptt time thromboplastin anticoagulants intended therapeutic range partialXx_NEWLINE_xXCluster 212: ast uln alt performed aminotransferase instead registration value lab practiceXx_NEWLINE_xXCluster 213: endotracheal endobronchial tumor evidence invading tract gi esophagus anus rectumXx_NEWLINE_xXCluster 214: syndrome patients gilberts known excluded trisomy necrolysis stevens history epidermalXx_NEWLINE_xXCluster 215: cholesterol mg dl level serum fasting mmol total draw gskXx_NEWLINE_xXCluster 216: investigational agents weeks receive past received planning patients receiving anticancerXx_NEWLINE_xXCluster 217: wound healing fracture ulcer non bone cabozantinib dose surgeries historyXx_NEWLINE_xXCluster 218: transaminase serum aminotransferase sgot glutamic oxaloacetic ast uln aspartate sgptXx_NEWLINE_xXCluster 219: maximum creatinine mg dl male age serum female years genderXx_NEWLINE_xXCluster 220: hemoglobin dl days registration prior randomization obtained step transfusions weeksXx_NEWLINE_xXCluster 221: strong cypc miscellaneous inducers cypa inhibitors wort st antibiotics agentsXx_NEWLINE_xXCluster 222: age bilirubin total upper uln limit normal direct times institutionXx_NEWLINE_xXCluster 223: bilirubin uln total gilbert serum known level upper normal enrolledXx_NEWLINE_xXCluster 224: significant unrelated organ dysfunction infections hepatic results interfere systemic proceduresXx_NEWLINE_xXCluster 225: phase ii arms randomized portion patients criteria registration weeks priorXx_NEWLINE_xXCluster 226: brain metastases trial excluded clinical known patients participants described trialsXx_NEWLINE_xXCluster 227: hepatitis known infection active virus chronic hiv viral patients immunodeficiencyXx_NEWLINE_xXCluster 228: gfr glomerular filtration rate min ml creatinine radioisotope clearance estimatedXx_NEWLINE_xXCluster 229: measurable disease ct recist patients imaging tomography mri assessed resonanceXx_NEWLINE_xXCluster 230: tumors verification patients original elevations relapse fetoprotein beta hcg intrinsicXx_NEWLINE_xXCluster 231: bilirubin gilberts uln total normal upper syndrome limit institutional unlessXx_NEWLINE_xXCluster 232: ul platelets mcl untransfused unsupported cells sequencing biopsy treatment tumorXx_NEWLINE_xXCluster 233: cypa inducers strong inhibitors medications drugs use substances concomitant moderateXx_NEWLINE_xXCluster 234: ctcae grade alopecia nci version institute terminology national unresolved commonXx_NEWLINE_xXCluster 235: fasting triglycerides mg dl equal cholesterol mmol lowering lipid valuesXx_NEWLINE_xXCluster 236: years age enrollment patients time performance scale months lansky studyXx_NEWLINE_xXCluster 237: anti pd antibody ctla programmed death cell targeting lymphocyte cytotoxicXx_NEWLINE_xXCluster 238: hbac glycosylated hemoglobin ac hb measurement equal registration days priorXx_NEWLINE_xXCluster 239: seizure disorder uncontrolled history patients seizures active generalized months medicationXx_NEWLINE_xXCluster 240: specific study provide informed consent entry patient prior representative legallyXx_NEWLINE_xXCluster 241: grade alopecia toxicities recovered prior related adverse toxicity therapy patientsXx_NEWLINE_xXCluster 242: myelosuppressive weeks nitrosourea anticancer received chemotherapy study prior dose knownXx_NEWLINE_xXCluster 243: cells platelets mm days prior registration obtained entry study experiencingXx_NEWLINE_xXCluster 244: qt interval qtc corrected msec qtcf fridericia formula electrocardiogram msXx_NEWLINE_xXCluster 245: mmol dl normalize mg despite intervention levels calcium hemoglobin adjustedXx_NEWLINE_xXCluster 246: overlap fields region result radiotherapy radiation cancer therapy prior studyXx_NEWLINE_xXCluster 247: ain anal stain intraepithelial neoplasia hsil proven biopsy cyclin junctionXx_NEWLINE_xXCluster 248: bowel gastrointestinal vomiting absorption nausea resection disease significantly inflammatory diseasesXx_NEWLINE_xXCluster 249: prohibited use bisphosphonates herbal concurrent dhea ephedra ginseng dehydroepiandrosterone yohimbeXx_NEWLINE_xXCluster 250: olaparib chemical composition compounds attributed reactions similar allergic biologic cediranibXx_NEWLINE_xXCluster 251: hgb hemoglobin dl obtained transfusions registration days prior allowed procurementXx_NEWLINE_xXCluster 252: live vaccine attenuated influenza vaccines vaccination flu seasonal dose studyXx_NEWLINE_xXCluster 253: consecutive undergone childbearing potential months orientation naturally meets sexual ligationXx_NEWLINE_xXCluster 254: upper limit normal creatinine uln institutional ast serum prothrombin altXx_NEWLINE_xXCluster 255: registration therapy days prior radiation treatment investigational immunotherapy chemotherapy mitomycinXx_NEWLINE_xXCluster 256: hiv cd immunodeficiency cluster differentiation positive virus human antiretroviral countXx_NEWLINE_xXCluster 257: fast mln maintain oral hour hours medication administration required bowelXx_NEWLINE_xXCluster 258: neuropathy grade peripheral greater patients severity exceeds registration sensory permittedXx_NEWLINE_xXCluster 259: intact capsules swallow able patients subprotocol subprotocols assigned general tabletsXx_NEWLINE_xXCluster 260: cooperative eastern ecog group oncology performance status ps patients scoreXx_NEWLINE_xXCluster 261: fcbp pregnancy lenalidomide agree effective method childbearing consecutive days commitXx_NEWLINE_xXCluster 262: allografts organ patients zubrod experimental expert expiratory explained exploratory exposedXx_NEWLINE_xXCluster 263: chemotherapy prior neoadjuvant patients received therapy treatment surgery radiation adjuvantXx_NEWLINE_xXCluster 264: lar representative legally authorized understand document willingness ability sign writtenXx_NEWLINE_xXCluster 265: sun exposure sunscreen protection excessive anticipated avoid willingness adequate useXx_NEWLINE_xXCluster 266: evaluable measurable disease patients parts radiologically recist ca participants clinicallyXx_NEWLINE_xXCluster 267: olaparib mother breastfeeding discontinued cediranib treated pregnant excluded women studyXx_NEWLINE_xXCluster 268: ppi pump proton inhibitor receiving dose study concomitant stop usingXx_NEWLINE_xXCluster 269: gilbert bilirubin total uln syndrome upper limit normal exception institutionalXx_NEWLINE_xXCluster 270: lactating breastfeed females plan infants eligible excluded exposure expert expiratoryXx_NEWLINE_xXCluster 271: wocbp women contraception nivolumab potential men postmenopausal childbearing use instructedXx_NEWLINE_xXCluster 272: bilirubin total upper institutional normal limit direct range sequencing allowedXx_NEWLINE_xXCluster 273: surgery major weeks recovered prior effects patients placement surgical studyXx_NEWLINE_xXCluster 274: women childbearing potential contraception adequate employ unwilling practice male menXx_NEWLINE_xXCluster 275: cancers skin patient thyroid advanced known active basal screening squamousXx_NEWLINE_xXCluster 276: breastfeed lactating agreed infants unless females eligible female pregnancy potentialXx_NEWLINE_xXCluster 277: cbc differential obtained blood count registration days complete step priorXx_NEWLINE_xXCluster 278: currently agents anti receiving cancer eligible patients anticancer platelet studyXx_NEWLINE_xXCluster 279: receiving agents eligible corticosteroid currently anti corticosteroids investigational cypa drugsXx_NEWLINE_xXCluster 280: permits psychological general follow health ability completion requirements required studyXx_NEWLINE_xXCluster 281: bilirubin mg dl total direct serum gilbert patient syndrome registrationXx_NEWLINE_xXCluster 282: cypc strong inducers inhibitors cyp cytochrome week preceding cypa alternativeXx_NEWLINE_xXCluster 283: malignancy melanotic cancer specific cervix situ skin carcinoma exceptions priorXx_NEWLINE_xXCluster 284: cavitating radiographic pulmonary lesion evidence subject participant extended extensive extentXx_NEWLINE_xXCluster 285: approaching biospecimens department regarding check release investigators submission pathology siteXx_NEWLINE_xXCluster 286: identity process ensure board approval order open entered date institutionXx_NEWLINE_xXCluster 287: bun urea nitrogen blood mg dl chloride bicarbonate glucose phosphataseXx_NEWLINE_xXCluster 288: measurable neuroblastoma lesions disease detected fluid mibg bone collections galliumXx_NEWLINE_xXCluster 289: tablets swallow able unable intact patients subject ability eligible chewedXx_NEWLINE_xXCluster 290: tissue tumor biopsy available archival submission slides paraffin patients blockXx_NEWLINE_xXCluster 291: immunotherapies activating conjugates brentuximab prior vedotin restrictions checkpoint purposes monoclonalXx_NEWLINE_xXCluster 292: creatinine gault cockcroft clearance min ml equation using calculated formulaXx_NEWLINE_xXCluster 293: cycle day herbal therapy week weeks prior contraceptives anticancer radiotherapyXx_NEWLINE_xXCluster 294: inhibitors azacitidine decitabine deacetylase histone hydroxyurea interferon tyrosine hematopoietic thalidomideXx_NEWLINE_xXCluster 295: autoimmune disease systemic syndrome replacement history patients sclerosis treatment arthritisXx_NEWLINE_xXCluster 296: cycle day investigational agent weeks treatment prior past agents receivedXx_NEWLINE_xXCluster 297: dipg stratum progressed progressive recurrent non patients irradiation refractory enrollmentXx_NEWLINE_xXCluster 298: dimension mm ct diameter lesion spiral longest recorded measurable accuratelyXx_NEWLINE_xXCluster 299: infection active requiring systemic antibiotics severe patients therapy fungal septicemiaXx_NEWLINE_xX